NELL1
Basics
Aliases:
This biomarker is also known as:- Protein kinase C-binding protein NELL1,
- Nel-related protein 1,
- NEL-like protein 1,
- NRP1,
- nel-like 1,
Description…
NELL1 is a cytoplasmic protein that contains epidermal growth factor (EGF)-like repeats. The encoded heterotrimeric protein may be involved in cell growth regulation and differentiation.
Attributes
| QA State: | Accepted |
|---|---|
| Type: | Genomic |
| Short Name: |
Organs
The following organs have data associated with this biomarker…
Esophagus
Attributes
| Phase: | Two |
|---|---|
| QA State: | Accepted |
Overview
Esphageal adenocarcinoma risk in Barrett's esophagus is increased 30- to 125- fold versus the general population. Among all Barrett's esophagus patients neoplastic progression occurs only once per 200 patient-years. Molecular markers (individual or in panel) would be useful to risk-stratify patients for more efficient surveillance endoscopy and to improve the early detection of progression.
Performance Comment
Promoter hypermethylation of NELL1 occurs early during Barrett's-associated esophageal neoplastic progression, and is a potential biomarker of poor prognosis in early-stage esophageal adenocarcinoma. Studies are ongoing.
Supporting Study Data
The following studies/protocols provide evidence supporting NELL1 indications for the Esophagus…
Barrett's Esophagus Methylation Profiles
We propose a nested case-control study of biomarkers in the setting of BE. By bringing together research institutions with large populations of patients with BE, we will perform a multi-center study of FISH and hypermethylation markers as possible prognostic factors in BE. The centers will select from their cohorts who have progressed to HGD or to adenocarcinoma of the esophagus ("progressors"), and who also donated samples prior to the development of cancer, when their histology was felt to be benign. These subjects will be compared to individuals who have been under endoscopic surveillance, but who have not progressed to HGD or EAC ("non-progressors"). Using this approach, we hope to identify promising markers for risk stratification in BE. We expect to be able to make successful application for a prospective study of markers identified in this case-control study.
View more about this studyBiomarker Characteristics Summary
| Notes | Sensitivity | Specificity | Prevalence | NPV | PPV | Specific Assay Type |
|---|---|---|---|---|---|---|
| Assessment of the classification accuracy of a single marker using ROC curve analyses show AUC for HPP1, p16, and RUNX3 are all significantly greater than 0.50. For NELL1, AUC (95% confidence interval) was 0.516 (0.420, 0.611). | 0.0 | 0.0 | 0.0 |
Decision Rule
PMID:17452981
Additional Study-Specific Protocols
Study-Specific Publications
- A multicenter, double-blinded validation study of methylation biomarkers for progression prediction in Barrett's esophagus.
- Hypermethylation of the nel-like 1 gene is a common and early event and is associated with poor prognosis in early-stage esophageal adenocarcinoma.
Study-Specific Resources
No study-specific resources defined.
Organ-Specific Protocols
No organ-specific protocols defined.
Organ-Specific Publications
No organ-specific publications defined.
Organ-Specific Resources
No organ-specific resources defined.
Studies
No associated studies or protocols found.
Publications
- A multicenter, double-blinded validation study of methylation biomarkers for progression prediction in Barrett's esophagus.
- Three-tiered risk stratification model to predict progression in Barrett's esophagus using epigenetic and clinical features.
- Hypermethylation of the nel-like 1 gene is a common and early event and is associated with poor prognosis in early-stage esophageal adenocarcinoma.
